BMRN Stock News & Catalysts – BioMarin Pharmaceutical

FEATURED

BioMarin to Participate in Upcoming Investor Conferences

Stifel Healthcare Conference, November 11 at 3:20 pm ESTUBS Global Biopharma Conference, November 16 at 9:20 am GMTJefferies Global Healthcare Conference, November 17 at 11:30 am GMTSAN RAFAEL, Calif., Nov. 4, 2026

Summary

Nov 4, 2026, 9:00 AM ·PRNewswire

RECENT

BioMarin Reports Third Quarter 2026 Financial and Operating Results

Third Quarter 2026 Total Revenues Increased 32% Y/Y to $1.025 billion; Growth Driven by 44% Increase in Metabolic Conditions Y/Y, and 12% Increase in Skeletal Conditions Y/YUpdates Full-year 2026 Guidance to Reflect

Nov 2, 2026, 4:03 PM ·PRNewswire

BioMarin Enters Into Exclusive Worldwide License Agreement With GC Biopharma and Hanmi Pharm for Investigational Next-Generation Enzyme Replacement Therapy, Adding a Second Potential Treatment for Fabry Disease

Agreement grants BioMarin worldwide rights (excluding Korea) to HM15421/GC1134A, a long-acting, subcutaneous, clinical-stage enzyme replacement therapy for Fabry diseaseBioMarin will make an upfront payment of $70

Oct 29, 2026, 8:45 AM ·PRNewswire

BioMarin to Host Third Quarter 2026 Financial Results Conference Call and Webcast on Monday, November 2, 2026, at 4:30pm ET

SAN RAFAEL, Calif., Oct. 26, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and

Oct 26, 2026, 9:00 AM ·PRNewswire

BioMarin Presents New Data Advancing Understanding of Achondroplasia and Hypochondroplasia Treatment at the American Society for Bone and Mineral Research Annual Meeting

New analysis showcases impact of VOXZOGO® (vosoritide) in foramen magnum and craniocervical junction growth in children with achondroplasia, including infantsSAN RAFAEL, Calif., Oct. 9, 2026 /PRNewswire/ -- BioMarin

Oct 9, 2026, 9:05 AM ·PRNewswire

BioMarin Appoints Cara Bauer as Chief People Officer

Ms. Bauer Brings More Than 25 Years of Experience in Human Resources, Across Biotechnology and Technology IndustriesAppointment Effective Oct. 5, 2026SAN RAFAEL, Calif., Oct. 5, 2026 /PRNewswire/ -- BioMarin

Oct 5, 2026, 4:05 PM ·PRNewswire

BioMarin Announces Five-Year Phase 3 Data for POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at World Muscle Society Annual Congress

Long-term data reinforce durable efficacy and safety of POMBILITI + OPFOLDA in late-onset Pompe diseaseSAN RAFAEL, Calif., Oct. 2, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced new data

Oct 2, 2026, 11:00 AM ·PRNewswire

BioMarin Announces Appointment of Robert Plenge, M.D., Ph.D., Chief Research Officer of Bristol Myers Squibb, to Board of Directors

SAN RAFAEL, Calif., Sept. 14, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced that the company has appointed Robert Plenge, M.D., Ph.D., to the company's Board of Directors, effective

Sep 14, 2026, 9:05 AM ·PRNewswire

BioMarin Announces Positive Results of Phase 3 VOXZOGO® (vosoritide) Study in Hypochondroplasia Published in NEJM Evidence

Detailed Phase 3 CANOPY-HCH-3 data in children living with hypochondroplasia also featured in a late-breaking oral presentation at the European Society for Paediatric Endocrinology (ESPE) 2026 Annual MeetingVOXZOGO

Sep 9, 2026, 9:05 AM ·PRNewswire

BioMarin to Participate in Upcoming Investor Conferences

Wells Fargo 21st Annual Healthcare Conference, September 9 at 3:00 pm ESTCantor Global Healthcare Conference 2026, September 10 at 10:20 am ESTCiti's 2026 Biopharma Back to School Conference, September 10 at 1:00 pm

Sep 2, 2026, 9:00 AM ·PRNewswire

BioMarin Announces Close of the Alesta Therapeutics Acquisition

Acquisition adds ALE1, a potential first oral therapy for hypophosphatasia to clinical pipeline SAN RAFAEL, Calif., Sept. 1, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) said today that it completed

Sep 1, 2026, 9:05 AM ·PRNewswire

BioMarin Announces Global Settlement with Ascendis Pharma A/S; Ascendis Will Pay Royalties to BioMarin on Yuviwel Sales in U.S., EU, Brazil and South Korea

Agreement Resolves all Pending Patent-Related Proceedings Between BioMarin and Ascendis SAN RAFAEL, Calif., Aug. 30, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that it has entered

Aug 31, 2026, 2:00 AM ·PRNewswire

BioMarin to Acquire Alesta Therapeutics to Gain ALE1, a Potential First Oral Therapy for Hypophosphatasia, Adding an Important Clinical Program to BioMarin's Pipeline

BioMarin to pay $275 million upfront, plus additional payments upon achievement of development and regulatory milestones Alesta to spin out all non-ALE1 assets to a new entity and Alesta employees to transfer to the

Aug 18, 2026, 8:30 AM ·PRNewswire

BioMarin to Participate at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 8:00AM ET in Boston

SAN RAFAEL, Calif., Aug. 10, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced management will present at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026,

Aug 10, 2026, 9:05 AM ·PRNewswire

BioMarin Reports Second Quarter 2026 Financial and Operating Results

Second Quarter 2026 Total Revenues Increased 20% Year-over-year to $990 millionStronger Growth Expectations Drive Increased Guidance for Full-year 2026 Total Revenues, VOXZOGO®, and Non-GAAP Diluted Earnings Per Share

Aug 6, 2026, 4:03 PM ·PRNewswire

BioMarin Pharmaceutical Inc. BMRN · News